VARI-SU2C

15 results.

November 30, 2017 Clinical trial investigates possible triple threat for lung cancer

A first-of-its-kind combination of medications may enable the immune system to better combat lung cancer, which claims more lives than any other cancer type and…

June 13, 2017 VARI-SU2C Epigenetics Dream Team launches new clinical trial to combat blood cancers

International collaboration pairs immunotherapy with an epigenetic drug to stop progression of chronic myelomonocytic leukemia and myelodysplastic syndrome into acute myeloid leukemia GRAND RAPIDS, Mich.…

March 7, 2017 New drug combination targets aggressive blood cancer

Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial GRAND RAPIDS, Mich. (March 7,…

December 30, 2016 What difference does a year make?

When it comes to biomedical research and science education, a year can make all the difference. In 2016, we celebrated Van Andel…

January 28, 2016 Phase II colorectal cancer clinical trial first to receive support, scientific oversight from Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team

GRAND RAPIDS, Mich. (Jan. 28, 2016)—The first clinical trial to move forward as part of the Van Andel Research Institute–

February 26, 2015 Van Andel Research Institute appoints leading cancer scientist Dr. Stephen Baylin as professor

GRAND RAPIDS, Mich. (Feb. 26, 2015)—Renowned cancer scientist and epigenetics expert Stephen Baylin, M.D., has accepted an appointment at Van Andel Research Institute (VARI) to help…

October 20, 2014 Stand Up To Cancer Epigenetics Dream Team continues with $7.5 million funding from Van Andel Research Institute

Grand Rapids, Michigan (October 20, 2014)— The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus…